Yanguang Cao1, Wei Gao, William J Jusko. 1. Department of Pharmaceutical Sciences School of Pharmacy & Pharmaceutical Sciences, State University of New York at Buffalo, 565 Hochstetter Hall, Buffalo, New York 14260, USA.
Abstract
PURPOSE: To provide a mechanism-based model to quantitatively describe GLP-1 pharmacokinetics (PK) and pharmacodynamics (PD) in rats. METHODS: Intravenous (IV), infusion (IF), subcutaneous (SC), and intraperitoneal (IP) doses of GLP-1 were administered after glucose challenge in healthy Sprague-Dawley rats. Blood was analyzed for GLP-1, glucose, and insulin. The PK-PD modeling was performed with ADAPT 5. The concentration-response curve was generated and analyzed in comparison with other incretin-related therapeutics. RESULTS: The PK of GLP-1 was described using a two-compartment model with a zero-order input accounting for endogenous GLP-1 synthesis. For SC and IP dosing, sequential zero-order and first-order absorption models reasonably described the rapid absorption process and flip-flop kinetics. In dynamics, GLP-1 showed insulinotropic effects (3-fold increase) after IV glucose challenge in a dose-dependent manner. The concentration-response curve was bell-shaped, which was captured using a biphasic two-binding site Adair model. Receptor binding of GLP-1 exhibited high capacity and low affinity kinetics for both binding sites (K(D) = 9.94 × 10(3) pM, K(2) = 1.56 × 10(-4) pM(-1)). CONCLUSIONS: The PK of GLP-1 was linear and bi-exponential and its PD showed glucose-dependent insulinotropic effects. All profiles were captured by the present mechanistic model and the dynamic analysis yields several implications for incretin-related therapies.
PURPOSE: To provide a mechanism-based model to quantitatively describe GLP-1 pharmacokinetics (PK) and pharmacodynamics (PD) in rats. METHODS: Intravenous (IV), infusion (IF), subcutaneous (SC), and intraperitoneal (IP) doses ofGLP-1 were administered after glucose challenge in healthy Sprague-Dawley rats. Blood was analyzed for GLP-1, glucose, and insulin. The PK-PD modeling was performed with ADAPT 5. The concentration-response curve was generated and analyzed in comparison with other incretin-related therapeutics. RESULTS: The PK ofGLP-1 was described using a two-compartment model with a zero-order input accounting for endogenous GLP-1 synthesis. For SC andIP dosing, sequential zero-order andfirst-order absorption models reasonably described the rapid absorption process and flip-flop kinetics. In dynamics, GLP-1 showed insulinotropic effects (3-fold increase) after IV glucose challenge in a dose-dependent manner. The concentration-response curve was bell-shaped, which was captured using a biphasic two-binding site Adair model. Receptor binding ofGLP-1 exhibited high capacity and low affinity kinetics for both binding sites (K(D) = 9.94 × 10(3) pM, K(2) = 1.56 × 10(-4) pM(-1)). CONCLUSIONS: The PK ofGLP-1 was linear and bi-exponential and its PD showed glucose-dependent insulinotropic effects. All profiles were captured by the present mechanistic model and the dynamic analysis yields several implications for incretin-related therapies.
Authors: Bronislava R Gedulin; Pamela A Smith; Carolyn M Jodka; Kim Chen; Sunil Bhavsar; Loretta L Nielsen; David G Parkes; Andrew A Young Journal: Int J Pharm Date: 2008-01-17 Impact factor: 5.875
Authors: David D'Alessio; Wendell Lu; William Sun; Shuqin Zheng; Qing Yang; Randy Seeley; Stephen C Woods; Patrick Tso Journal: Am J Physiol Regul Integr Comp Physiol Date: 2007-09-26 Impact factor: 3.619
Authors: R Mann; N Nasr; D Hadden; J Sinfield; F Abidi; S Al-Sabah; R López de Maturana; J Treece-Birch; A Willshaw; D Donnelly Journal: Biochem Soc Trans Date: 2007-08 Impact factor: 5.407
Authors: Kaare V Grunddal; Samuel A J Trammell; Cecilie Bæch-Laursen; Daniel B Andersen; Stella F S Xu; Helle Andersen; Matthew P Gillum; Seyed M Ghiasi; Ivana Novak; Björn Tyrberg; Chien Li; Mette M Rosenkilde; Bolette Hartmann; Jens J Holst; Rune E Kuhre Journal: Diabetologia Date: 2022-03-24 Impact factor: 10.460